Dishman Carbogen Amcis has reported its unaudited financial results in line with Ind AS 34 standards for the quarter ended 30th June, 2021, after the company’s Board of Directors took the same on record at a meeting yesterday, the company said in a statement.
Further, according to the statement, the financial statement highlights of the Q1FY2021 are as follows:
- Consolidated net sales for Q1, FY22 at Rs 550.73 crores, grew four per cent as compared to the previous quarter at Rs 529.32 crores, and up 16.1 per cent compared to the same quarter the previous year at Rs 474.41 crores
- Employee benefit expenses were at Rs 239.03 crores, up 8.8 per cent QoQ from Rs 219.77 crores
- Total Expenses amounted to Rs 537.17 crores, up two per cent QoQ
- EBITDA for the quarter stands at Rs 100.64 crores, with an EBITDA margin of 18.3 per cent, compared to 16.7 per cent margin in the previous quarter, and 9.1 per cent margin in the previous year’s quarter
- Profit Before Tax (PBT) was at Rs 23.97 crores v/s a loss of Rs 13.79 crores in the previous quarter
- Net Profit After Tax at Rs 16.02 crores, compared to a net loss of Rs 135.02 crores in the previous quarter, and compared to a net loss of Rs 21.43 crores for the YoY quarter
- Capital expenditure for the quarter was approximately $12.18 million (approximately Rs 95 crores), which majorly includes capex at Swiss and French sites
- Net debt excluding lease liabilities was $101 million as on 30th June, 2021, remained the same QoQ
Commenting on the results, Harshil Dalal, Global CFO, Dishman Carbogen Amcis, said, “DCAL has posted robust growth in net revenue during the quarter on account of growth in CRAMS revenue with CRAMS India revenue doubling due to re-commencing production for CRAMS customers from Bavla site in India. CRAMS UK revenue also posted a strong growth contributing to the overall CRAMS revenue, while the marketable molecules’ revenue also rose strongly primarily due to Carbogen Amcis BV revenue spiralling by over 60 per cent.”